Appendix 4E and Preliminary Financial Report
Filed with ASX · · 29 pages · English
Summary by 6ix AI
The report indicates a revenue increase from ordinary activities compared to the previous year, while the loss after tax attributable to owners has decreased significantly. No dividends were declared or paid during the reporting period, and the report includes unaudited summary consolidated financial statements. The financial statements reflect a net asset position for the company, although there are concerns regarding funding for ongoing research and development activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Invion
- Expansion of Territory Rights to USA, Canada and Hong Kong
- INV043 Effective Against Anal Cancer SCC In Vitro
- Response to ASX Aware Query
- Photosoft Shows Activity Against Zika Virus
- Activities Report and Appendix 4C
Later from Invion
- Photosoft Territory Expanded to South Korea for Cancer
- Investor Presentation
- Major Milestone towards Clinical Trials
- AGM Presentation
- Agreement with Dr.inB to develop Photosoft treatment for HPV
Follow Invion into a list and get an email when it puts out news.
Follow Invion